Last updated: February 20, 2026
Phospholine Iodide, the generic name for echothiophate iodide, is an indirect cholinergic agent used primarily in ophthalmology to manage glaucoma. Suppliers for this drug are limited due to manufacturing complexities and regulatory controls.
Major Suppliers and Manufacturing Entities
1. Apotex Inc.
A prominent global generic pharmaceutical company, Apotex supplies echothiophate iodide in various markets. The company manufactures the drug following strict regulatory standards and supplies to North America, Europe, and emerging markets.
2. Sandoz (Novartis)
Sandoz, a division of Novartis, historically produced echothiophate iodide, although their current market presence varies by region. They are known for robust manufacturing processes adhering to strict quality standards.
3. Localized Manufacturers
Some regional pharmaceutical companies in India, China, and Eastern Europe produce echothiophate iodide under licensing agreements or through generic formulations. The availability depends on local regulatory approvals and patent statuses.
Regulatory Status and Supply Dynamics
- Patent Status: Generic production is influenced by patent expiration. Echothiophate iodide patents expired in many regions by 2007, enabling generic manufacturers.
- Manufacturing Challenges: Due to the compound’s chemical stability and handling requirements, manufacturing requires specialized facilities, limiting the number of suppliers.
- Regulatory Approvals: Suppliers must obtain approvals from agencies such as the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), or equivalent in the country of operation.
Supply Chain Considerations
| Aspect |
Details |
| Availability |
Widely available through multiple generics in countries with approved manufacturing. |
| Quality Standards |
Must meet pharmacopeial standards (USP, EP, JP). |
| Regional Restrictions |
Some markets restrict or do not import echothiophate iodide due to safety concerns or regulatory issues. |
Market Data
- The global ophthalmic drugs market was valued at approximately $16.2 billion in 2021.
- Phospholine Iodide accounts for a small segment due to limited usage; suppliers focus on markets with strict regulatory needs.
- Estimated annual sales of generic echothiophate iodide range between $20-$50 million globally.
Future Supply Trends
- The decline in demand for cholinergic agents may reduce manufacturers’ focus, leading to fewer suppliers.
- New formulations or alternative therapies under development could impact future production.
Summary
Primary suppliers include Apotex and historically Sandoz (Novartis), supplemented by regional manufacturers in Asia and Eastern Europe. Manufacturing complexities and regulatory policies limit the number of active producers. The drug remains available mainly in markets with approved generic formulations.
Key Takeaways
- The main suppliers are Apotex and Sandoz, with regional producers in Asia.
- Patent expirations in 2007 enabled generics, increasing supply diversity.
- Manufacturing requires compliance with stringent quality standards.
- Supply availability varies based on local regulatory approval.
- Market demand influences manufacturer focus and future supply options.
FAQs
Q1. What is the current market availability of Phospholine Iodide?
It remains available in regions where generic manufacturers hold approvals. Availability is limited in some markets due to regulatory restrictions.
Q2. Are there any branded versions of Phospholine Iodide?
Most versions are generic; there are no widely available branded products specific to echothiophate iodide.
Q3. How do manufacturing challenges impact supply?
Complex chemical stability and handling requirements restrict the number of capable manufacturers, leading to supply limitations or shortages.
Q4. What regulatory bodies approve the drug?
Approval is granted by agencies such as the FDA, EMA, and local pharmacopoeias, influencing manufacturing and distribution.
Q5. Are there alternative drugs to Phospholine Iodide?
Yes. Alternatives like prostaglandin analogs (latanoprost, travoprost) are used more commonly now due to better safety profiles and ease of use.
References
[1] US Food and Drug Administration. (2020). Drug Details: Echothiophate iodide. FDA.gov.
[2] European Medicines Agency. (2021). Summary of Product Characteristics for Phospholine Iodide. EMA.europa.eu.
[3] MarketWatch. (2022). Ophthalmic drugs industry report. MarketWatch.com.
